The aims of the current phase I/II trial are to determine the maximum tolerated dose of the drug candidate BZL101 and tumor response in women with late stage breast cancer. The trial will enroll 80 volunteers who have advanced measurable breast cancer and have had no more than two prior third line cytotoxic treatments.
BZL101 is an oral drug designed to induce cancer cell apoptosis, or cell death, while leaving normal cells unaffected. Results from the company’s initial FDA-approved phase I clinical trial showed BZL101 was safe in a cohort of women with advanced breast cancer.
“We are excited to bring our second Bionovo drug candidate into phase II clinical testing to further advance our pipeline and to find safer, less toxic therapeutic treatment options for women with advanced breast cancer,” stated Isaac Cohen, CEO and president of Bionovo.